Loading...
Market
When will the first drug approval by the merged entity occur?
2
Resolution / Starting Odds
Before June 30, 2025 • 25%
Between July 1, 2025 and December 31, 2025 • 25%
After December 31, 2025 • 25%
No drug approval by December 31, 2025 • 25%
Official announcements from the merged entity or regulatory bodies like the FDA or EMA
Story
Recursion and Exscientia Announce $688 Million All-Stock Merger
Aug 8, 2024, 12:52 PM
Recursion Pharmaceuticals and Exscientia have announced a definitive agreement to merge, creating a global leader in AI-driven drug discovery. The merger, valued at $688 million, will be an all-stock deal. This strategic move combines Recursion's high throughput target biology and supercomputing capabilities with Exscientia's generative AI drug design and chemistry automation. The merger aims to accelerate drug discovery, delivering better treatments to patients faster and at lower costs. The combined entity will also gain access to partnerships with large pharmaceutical companies like Sanofi and Merck KGaA.
View original story
Similar markets
FDA (USA) • 25%
EMA (Europe) • 25%
PMDA (Japan) • 25%
Other • 25%
Yes • 50%
No • 50%
Adaptimmune (Afami-cel) • 25%
Checkpoint Therapeutics (Cosibelimab) • 25%
Mirati Therapeutics (Adagrasib-Cetuximab) • 25%
Other • 25%
Yes • 50%
No • 50%
More than 3 new drugs • 25%
2-3 new drugs • 25%
1 new drug • 25%
No new drugs • 25%
Alzheimer's drug • 25%
Multiple Sclerosis drug • 25%
Neuromuscular drug • 25%
Other • 25%
Q1 2026 • 25%
Q2 2026 • 25%
Q3 2026 • 25%
Q4 2026 or later • 25%
Yes • 50%
No • 50%
